PFIZER INC (PFE) stock intrinsic value fair value estimate & owner earnings analysis

Pfizer sells prescription medicines and vaccines worldwide: $62.6 billion of revenue in 2025 ($63.6 billion in 2024). The largest products in 2025 were Eliquis ($8.0B, with Bristol Myers Squibb), the Prevnar pneumococcal vaccines ($6.5B), the Vyndaqel family for ATTR heart disease ($6.4B), Comirnaty ($4.4B), Ibrance ($4.1B), Paxlovid ($2.4B) and Xtandi ($2.2B, with Astellas). Oncology, built largely on the roughly $43 billion Seagen purchase in December 2023 (Padcev, Adcetris, Tukysa, Tivdak), brought in $16.8B. What the business earns. We measure owner earnings as operating cash flow with working-capital swings removed, minus stock compensation and the capital spending needed to keep the business running. Large non-cash charges are added back, mainly amortization of acquired product rights and asset impairments ($4.2B in 2024, $5.3B in 2025). The working-capital outflows we excluded in 2024-2025 are mostly one-time items: unwinding COVID-era balances and the yearly installments of the 2017 tax-reform repatriation tax, whose last $2.6B payment was due in April 2026. Pfizer as it exists today dates from the Seagen deal and the end of the COVID boom, so we anchor on 2024-2025 only. Before interest, owner earnings were $2.71 per share in 2024 and $2.87 in 2025. We trim that to $2.70, about $15.4B a year, because 2024 included about $1.2B of Paxlovid revenue that brought in no cash that year. The 2021-2022 COVID peak ($3.15 and $5.52 per share after interest) and the 2023 write-down year ($1.13) are left out of the anchor. The patent cliff is the story. Products whose main U.S. patent runs out between 2026 and 2028 brought in about $22.7B in 2025, or 36% of revenue: Xeljanz and Adcetris (2026); Vyndaqel (December 2026, with an extension to 2028 applied for but not granted); Ibrance and Xtandi (2027); and Eliquis, where settlements allow generics on April 1, 2028. These are high-margin products, so they produce most of today's cash. Medicare's negotiated prices arrive even sooner: Eliquis from January 2026, Ibrance and Xtandi from January 2027, Xeljanz from January 2028. In September 2025 Pfizer also agreed with the U.S. administration to bring some U.S. prices closer to those in other rich countries, in return for a three-year break from tariffs. Because the amortization of acquired products is added back, their wear-out is charged here, in the falling path, not in the starting level. The first half of 2026 already shows the turn. Revenue rose to $29.5B from $28.4B, but owner earnings before working capital fell to about $5.5B from $7.1B. Cost of sales rose $1.0B, research spending rose $0.6B as Pfizer began funding the obesity programs bought with Metsera in 2025, and a $4.3B impairment led to a second-quarter net loss. In 2025 business cash flow per share grew 6%. Our base case starts 2026 13% lower, below that trailing rate. Base case (about $21 per share). Most of the patent-cliff products lose 70-75% of their profit by 2030. COVID sales keep shrinking. Recently launched products with patents into the 2030s (Padcev, Nurtec, Abrysvo, Lorbrena, Elrexfio, Prevnar 20) keep growing at about half their 2025 pace through 2030. That growth is credited only because the products are already approved and their uptake has been shown for several years. Business cash flow falls from about $13.4B in 2026 to a trough of about $8.4B in 2030, then recovers to about $10B by 2035 and holds there. That $10B rests on two pieces of evidence. First, over the past decade or so, roughly $8-11B a year of research spending produced Ibrance, Prevnar 20, Abrysvo, Lorbrena, Elrexfio and the heart-disease use of Vyndaqel. Second, before COVID and before about $73B of cash acquisitions in 2022-2025, the remaining business earned $9.5-9.8B a year on about $41B of revenue (2019-2020). We give the obesity pipeline, unapproved drugs and cost savings not yet achieved no value. Pfizer reports $5.1B of savings through 2025 and targets $0.6B more by end-2026 plus about $0.9B more from manufacturing by 2027. Business value is about $169B. At June 28, 2026 Pfizer owed $63.2B of bonds and loans and held $10.7B of short-term investments plus about $1B of cash. Its bonds carry mostly fixed coupons averaging 2.9%-5.3% by maturity group, out to 2065, below our 6% rate, which makes the debt worth about $6.3B less than its face value to us. Adding $0.3B of outside owners' stakes, net debt is about $46.5B, leaving about $122B, or $21.39 per share. Bear case (about $14.50). This case uses only risks named in the filings. A court could invalidate the Eliquis formulation patent, which would let generics launch on November 21, 2026. The Vyndaqel extension could be denied. U.S. price cuts could deepen under the government agreement and Medicare negotiation. The run of $3-5B yearly write-downs on acquired assets continues, so the pipeline delivers less. Business cash flow drops to about $7.0B in 2029 and $6.8B in 2030 and settles near $7.5B, about the 2018 level of the business that remains. With refinancing at higher rates, the debt benefit is halved. Business value is about $133B, net debt about $49.6B, leaving about $83B ($14.53 per share). Interest of about $2.7B a year stays covered more than twice even at the low point. Bull case (about $32). The Vyndaqel extension is granted, recent launches keep their 2025 pace, and the announced cost programs are fully delivered. Cash flow bottoms near $11.8B in 2029 and rebuilds to $14B by 2035. Business value is about $228B, less $46.5B of net debt, leaving about $182B ($31.85 per share). Margin-of-safety price. Outcomes range widely, from $14.50 to $32. Timing depends on court rulings and Medicare price decisions, so we set the margin-of-safety price at $13. From that price the bear-case value alone, plus one year of the current $1.72 dividend, implies about 25% in a year. If the shares reach the base value within about three years, the base case implies roughly 20% a year or better including dividends. Note that the base case implies the dividend (about $9.8B paid in 2025) will eventually have to shrink, because owner earnings after interest at the 2030 low are well below that amount. Change from our previous estimate. In August we valued the shares at roughly $1.50 / $8.50 / $19.50. That work used higher discount rates. It subtracted debt from a figure already after interest, counted cash without the $10.7B of short-term investments, and charged one-time tax and COVID working-capital outflows against ongoing earnings. Correcting these raises every case. The new view of the next five years is harsher than before, with steeper patent losses and a lower 2026 start. What we could not confirm. From the filings available to us, we could not identify which assets the $4.3B second-quarter 2026 impairment relates to.